Importantly, by contrast to direct topical administration insulin, which can cause life-threatening hypoglycemia [25], pharmacological inhibition of IDE possesses no intrinsic risk of triggering hypoglycemia [32–34]. The gene discussed is INS; the disease is Hypoglycemia.